Orion Oyj

Orion Oyj

ORINY

$47.16

Updated: 23/09/2026, 08:28:42

Market Cap
$26.55B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
FI
Stock valuation chart
One-year closing share-price history for ORINY
Company Profile

Orion Oyj is a Finnish pharmaceutical company specializing in the creation, production, and commercialization of medicines for both human and animal health, as well as the active components (APIs) essential for drug formulation. Its operations extend across Finland, the Nordic region, wider Europe, North America, and various international markets. The company's diverse product portfolio encompasses both prescribed medications and over-the-counter (OTC) healthcare solutions. This includes notable offerings such as Nubeqa for prostate cancer therapy; Dexdor and Precedex, utilized as sedatives in intensive care settings; Stalevo and Comtess/Comtan addressing Parkinson's disease; Simdax for acute heart failure decompensation; and Fareston for breast cancer management. Additionally, a range of Easyhaler devices—like Salmeterol/fluticasone, Budesonide/formoterol, Formoterol, Budesonide, Beclomet, and Buventol—are provided for managing asthma and chronic obstructive pulmonary disease (COPD). Beyond human medicine, the firm supplies a suite of veterinary medications, including products such as Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie. It also produces APIs for both proprietary and generic pharmaceutical products and offers specialized contract manufacturing capabilities. Furthermore, Orion Oyj distributes veterinary medicines manufactured by other global pharmaceutical entities. Its clientele spans a broad spectrum of healthcare stakeholders, from specialist and general physicians, veterinarians, and pharmacists to hospitals, healthcare centers, clinics, laboratories, and directly to consumers who own pets. Strategic alliances include a collaboration with Propeller Health aimed at integrating its Easyhaler® product range for asthma and COPD management with digital health solutions. Additionally, it holds a research collaboration and licensing deal with Alligator Bioscience AB (publ) focused on pioneering novel bispecific antibody-based cancer treatments. Established in 1917, Orion Oyj maintains its corporate headquarters in Espoo, Finland.

USD
OTC
CEO: Aino Anna Liisa Hurme
Employees: 4,029
https://www.orionpharma.com
Asset Summaries
Latest generated summaries for ORINY

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for ORINY.
Share price
$47.16
Market cap
$26.55B
Exchange
OTC
Currency
USD
CEO
Aino Anna Liisa Hurme
Employees
4,029
IPO date
09/12/2014
Beta
0.288
Last dividend
$0.00
Day range
$46.64 – $47.16
52-week range
$30.89 – $47.16
1-day performance
0.00%
1-year performance
52.67%
Current drawdown (1Y)
0.00%
CIK
N/A
CUSIP
68628Y104
ISIN
US68628Y1047
Created
07/12/2025, 05:37:36
Last update
23/09/2026, 08:28:42

Track Orion Oyj with an AI analyst

See which prediction-market events move ORINY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to ORINY from your Railway `news_articles` table.

No news found for this symbol.